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Abstract
Heterogeneous patterns of mutations and RNA expression have been well documented in invasive 
cancers. However, technological challenges have limited the ability to study heterogeneity of 
protein expression. This is particularly true for pre-invasive lesions such as ductal carcinoma in 
situ of the breast. Cell level heterogeneity in ductal carcinoma in situ was analyzed in a single 5um 
tissue section using a multiplexed immunofluorescence analysis of 11 disease-related markers 
(EGFR, HER2, HER4, S6, pmTOR, CD44v6, SLC7A5 and CD10, CD4, CD8 and CD20, plus 
pan-cytokeratin, pan-cadherin, DAPI, Na+K+ATPase for cell segmentation). Expression was 
quantified at cell level using a single cell segmentation algorithm. K-means clustering was used to 
determine co-expression patterns of epithelial cell markers and immune markers. We document for 
the first time the presence of epithelial cell heterogeneity within ducts, between ducts and between 
patients with ductal carcinoma in situ. There was moderate heterogeneity in a distribution of 8 
clusters within each duct (average Shannon Index 0.76; ranged 0 – 1.61). Furthermore, within each 
patient, the average Shannon Index across all ducts ranged from 0.33 to 1.02 (S.D. 0.09 to 0.38). 
As the distribution of clusters within ducts was uneven, the analysis of 8 ducts might be sufficient 
to represent all the clusters i.e. within- and between-duct heterogeneity. The pattern of epithelial 
cell clustering was associated with the presence and type of immune infiltrates, indicating a 
complex interaction between the epithelial tumor and immune system for each patient. This 
analysis also provides the first evidence that simultaneous analysis of both the epithelial and 
immune/stromal components might be necessary to understand the complex milieu in ductal 
carcinoma in situ lesions.
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Introduction:
Cellular heterogeneity presents a major problem in treating cancer. Tumor heterogeneity has 
been elucidated in detail using next generation sequencing (1–4). Studies have identified 
substantial tumor heterogeneity with mutations in spatially distinct parts of the tumor in 
several cancer types. More recently, next generation sequencing techniques using single 
tumor cells from invasive cancers have increased our ability to understand cellular 
heterogeneity (5). Understanding heterogeneity in protein expression is still a major 
challenge. This is even more problematic in small pre-invasive lesions such as ductal 
carcinoma in situ.
Ductal carcinoma in situ, the most common type of pre-invasive lesion, is being detected 
with increasing frequency with the advent of mammographic screening. Surgery is the 
mainstay for the treatment of ductal carcinoma in situ and on the clinic-pathological 
features, this may be followed by radiotherapy and/ or endocrine therapy (6). The qualitative 
assessment of histological grade, expression of single protein biomarkers and more recently, 
mRNA analysis (Oncotype DX Breast DCIS Score®) (7–9) have been used to make these 
decisions. However, these approaches do not fully reflect the degree of cellular 
heterogeneity of ductal carcinoma in situ, cellular interactions with surrounding 
microenvironment and other cell types. Using quantitative multiplexed immunofluorescence 
of a single formalin fixed paraffin embedded tissue section (10), we have for the first time 
investigated the degree of cellular heterogeneity by analyzing the expression and co-
expression of biologically relevant proteins at a single cell and subcellular levels in tissues in 
ductal carcinoma in situ and correlations with immune response. In total, 14 protein markers 
were multiplexed on single formalin fixed paraffin embedded section per patient, including 
EGFR, HER2, HER4, pmTOR, CD44v6, SLC7A5, CD10, CD4, CD8 and CD20. Pan-
cytokeratin, pan-cadherin, DAPI, Na+K+ATPase were used for epithelial and stromal cell 
segmentation. Markers were selected based on previously reported expression in ductal 
carcinoma in situ lesions and association with recurrence and included members of the ErbB 
family (EGFR, HER2, HER4) (11–17) ); pmTOR, which has been associated with 
autophagy pathway in ductal carcinoma in situ and breast cancer (18). CD44v6 expression 
has been reported in expressed in ductal carcinoma in situ, invasive cancers, but not in 
benign tissue (19) and is also reported to be a putative stem cell marker (20). It may also 
facilitate receptor tyrosine kinase signaling via binding to its heparin sulfate side chain (21). 
SLC7A5/LAT1 is an amino acid exchange transporter that has not been studied in ductal 
carcinoma in situ, but is upregulated in breast cancers at both primary and metastatic sites 
(22). Increased expression correlates with poor prognosis and disruption leads to the 
inhibition of mTOR (23). CD10 is expressed on myoepithelial cells and loss of expression 
may be associated with invasive disease (24). Lymphocyte infiltration in triple negative and 
HER2 positive subtypes have been associated with prognosis in ductal carcinoma in situ and 
breast cancer, with CD4+ T-helper cells responsible for facilitating antigen presentation; 
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FOXP3+CD4+ regulatory T-cells supporting proliferation of B-cells and CD8+ cytotoxic T-
cells required for tumor destruction (25–28). The expression pattern of individual markers 
(both epithelial and stromal) in the current study conformed to that described in prior 
publications and hence is not described in detail herein.
Materials and Methods:
Antibody Screening and Selection-
Antibody validation processes have been previously described (10). Briefly, for each protein 
target examined in the study, a minimum of 3 commercial initial antibodies were compared 
in parallel using Cy3 or Cy5 conjugated secondary antibodies (Jackson Immunologicals). 
Antibodies were assessed based on staining specificity and sensitivity characteristics using a 
multi-tissue array that contained breast and other tissue types (Pantomics #MNT241) and 
compared to patterns reported in literature and or the Human Protein Atlas (http://
www.proteinatlas.org/). Where possible, antibodies used in clinical immunohistochemistry 
lab were included in the screenings. Slides were cleared and processed for antigen retrieval 
as previously reported (10) and all antibodies used at manufacturer recommended 
concentrations with 1 hour room temperature incubation. Specificity was determined based 
on localization pattern and comparison to non-specific antibodies of the same isotype. The 
strongest staining and most specific antibodies were further tested to ensure that the antigen 
was not altered by the dye inactivation process by comparing staining on samples that were 
untreated or treated 1, 5, or 10 times with the dye inactivation process (used to multiplex) 
and subsequent washing in PBS prior to antibody staining. The 14 markers were: pan-
cytokeratin, pan-cadherin, NaKATPase, SLC7A5, CD10, EGFR, HER2, HER4, S6, 
phospho-mTOR, CD44v6, CD4, CD8, and CD20.
Antibody Conjugation-
After selection, each antibody was conjugated with either Cy3 or Cy5 bis-NHS-ester dyes 
using standard protocols as previously described (10). Where needed, antibodies were 
purified from BSA, glycerol, or other stabilizing agents by protein A/G purification. 
Antibodies were initially conjugated at 2 different loading concentrations (2 and 4 dyes/
antibody) and staining performance was compared to the secondary-detected antibodies used 
in the screening stage.
Clinical Cohort:
13 de-identified cases of ductal carcinoma in situ were selected from the archives at 
Singapore General Hospital. The criteria for the selection were as follows 1) they were 
excision specimens 2) patients did not have invasive cancer 3) patients had additional blocks 
of ductal carcinoma in situ 4) multiple foci of ductal carcinoma in situ were present in the 
sections examined. Clinical information on the samples included age at diagnosis, size (mm) 
of ductal carcinoma in situ. An initial histopathological review was performed to confirm the 
diagnosis of ductal carcinoma in situ. The diagnosis of ductal carcinoma in situ was 
confirmed independently by two pathologists. A second tier of histological analysis was 
performed using pseudo-H&E digital images of the stained slides to study the relationships 
between the epithelial and stromal components and to quantify the different elements (see 
Gerdes et al. Page 3
Mod Pathol. Author manuscript; available in PMC 2018 October 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
below) within any given field. Multiple fields were quantified from each case. Data for the 
expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor (HER2) was obtained from the files of Singapore General Hospital. 
These stains were performed as a part of standard of care using ASCO-CAP guidelines to 
define positivity (29, 30).
Multiplexed Immunofluorescence Staining-
Multiplexed immunofluorescence staining was performed as previously described (10). 
Slides were initially baked at 60°C for 1 hour prior to clearing with xylene and rehydration 
through a graded series of ethanol. Two-step antigen retrieval was performed as previously 
described (10) and slides were blocked overnight in 4% BSA, 10% donkey serum, in PBS at 
4°C. After blocking, slides were stained with DAPI (1ug/ml), cover-slipped with anti-fade 
mounting media, and background images collected in DAPI, eGFP, Cy3, and Cy5 filter 
channels. For initial imaging, a 10X objective was used, and the whole tissue imaged, 
followed by image stitching to create a composite image of the sample. The large 
representation of the whole tissue was then converted to a pseudo-H&E image and used for 
mapping specific fields for further interrogation for each slide. A minimum of 30 fields were 
chosen for each histological section and included ductal carcinoma in situ, and surrounding 
stromal areas. After selection, microscope coordinates were determined and exported for use 
during imaging calibrated to a 20X objective. Slides were then sequentially stained, imaged 
with a 20X objective, dyes inactivated, and re-stained iteratively for a total of 14 markers 
under analysis (Table 1). All dye conjugated antibody stains were for 1 hour at room 
temperature, and slides were processed for staining and washing using a Biocare autostainer. 
A summary table of the specific staining sequence and exposure times are provided in 
Supplemental data. All fields of view acquired were subsequently re-evaluated by a 
pathologist for % tumor, % normal epithelial, % immune along with pathological grading. 
The % tumor pertains to the % of any given field of view that is represented by ductal 
carcinoma in situ. Similarly, the amount in each field of view was quantified for normal 
epithelium and immune cells. The complete image set was then reviewed for tissue quality 
(tissue loss or damage) and image analysis segmentation output.
Image processing and statistical analyses
Data preprocessing—After data collection, images from all rounds are registered to the 
initial round using the DAPI channel to determine any offsets. Images are then processed for 
field flattening and autofluorescence is subtracted. Several quality control steps were applied 
to ensure usable cell level intensities. In addition, manual scoring of tissue quality and 
segmentation for every “Field Of View” was performed; this resulted in exclusion of 35 field 
of views. For total 13 Slides, 416 field of views were remaining for further analysis.
Single cell analysis algorithm segments cells in the epithelial compartments using DAPI, 
pan-cytokeratin, S6, and NaKATPase, and just DAPI in the stromal compartment, as 
previously described (10). Expression of SLC7A5, CD10, EGFR, HER2, HER4, S6, 
phospho-mTOR, CD44v6 in the epithelial masked area was quantified at single cell level 
and metrics included mean intensity, maximum intensity, and standard deviation in the 
membrane, cytoplasm and nucleus. Quality checks and filtering at single cell level were also 
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performed. For example, epithelial cells were required to have the following characteristics: 
1) maximum 1–2 nuclei per cell; 2) Each sub-cellular compartment (nucleus, membrane, 
cytoplasm) area had to have > 10 pixels; and 3) nuclei in each round of staining have to have 
perfect alignment to the first round of staining (automatic tissue quality index=1 at each 
round, which is the correlation between DAPI in each image). After the quality control 
steps, exposure time was re-set at 200 milli-second for cy3, 500 millisecond for cy5, 50 
millisecond for eGFP and 20 millisecond for DAPI across all slides and markers. Finally, 
biomarker intensities were log2 transformed. After all the pre-processing and quality control 
steps (and exclusion of the control slides), we have 379,408 epithelium cells of 13 cases for 
all the markers with available valid cell level intensities.
For immune cell analysis (CD4, CD8 and CD20), support vector machine classification was 
used to classify immune cells. Model training was carried out by manual annotations using a 
tool developed in “FIJI” program to annotate CD4, CD8 and CD20 positive cells for ground 
truth and model training. These features were used to assign each cell in the image a 
probability of being a member of the CD4+, CD8+, or CD20+ classes. Ultimately, each cell 
in the image was assigned to one of the following classes: negative for all immune markers; 
cytotoxic T-cells (CD8+); T-helper cells (CD4+) and B-cells (CD20+).
Cellular Heterogeneity and Shannon Index methods
Shannon diversity index was applied to the cell data to measures the diversity of cells within 
the dataset using the proportion of each cell types. It is a quantitative index that was 
originally developed by Shannon (31) to quantify uncertainty in strings of text. It has been 
applied to ecology applications to quantify to proportion of individuals belonging to a 
species in a given dataset, and quantifies the uncertainty in predicting the species identity of 
an individual taken at random from the dataset. It is calculated as the following:
H = − ∑
i = 1
R
pilnpi where R is the total number of clusters and pi is the proportion of the 
cluster i. The higher H is, the more heterogeneity is present in the dataset. For example, in 
the case of this study, if all the cells from the same duct are assigned to one K-mean cluster, 
the H value approaches to zero. However, if all the cells come from multiple clusters evenly, 
the H value is high and approaches to lnR= ln(8)= 2.08 (R=8 clusters in our dataset). A 
Shannon index was computed for each duct, then for a single patient, the average and 
standard deviation of Shannon index from all their imaged ducts was calculated to describe 
duct-to-duct diversity.
K-means clustering algorithm was applied to all cellular data (379,408 cells for all 13 
patients) in R for K=2,3, …,15 and repeat 10 runs with randomly selected initial K centroids 
for each K. To help determine the best K, we used Consensus Clustering (R library 
ConsensusClusterPlus) and based on the Delta area metric. The best results were obtained 
with a cluster solution using the following 7 epithelial markers: EGFR, HER2, HER4, 
SLC7A5, pmTOR, CD44v6 and CD10. A heatmap was plotted to show cluster definition. 
Using cell IDs and spatial coordinates, the epithelial cell clusters were then overlaid with the 
tissue images using a color-coding schema.
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Once the clusters were defined at cell level, the compositions of clusters for each patient and 
tumor field of views was calculated using level enrichment statistics. Each patient was 
represented by a vector of 8 elements with each element being the percentage of cells falling 
in that cluster and all the elements adding up to 100 percent. A pie chart was also generated 
to visually assess the cell type variation across all patients. The same statistic was also 
calculated for each field of view and the relationship between enrichment and the 
histological scores at patient level was assessed.
For the immune markers (CD4, CD8, CD20) we limited analysis to the stromal region 
(543,355 cells in total) as described above. The patient level immune profiles were then 
summarized by the proportion of CD4 positive cells relative to stromal cells, the proportion 
of CD8 positive cells, the proportion of CD20 positive cells, the total T cells (CD4+CD8), 
the CD4 to CD8 ratios, and the T cell to B cell ratios. The relationship between immune 
profiles and traditional histological scores at patient level was analyzed. The correlation 
between epithelium cell clusters and stromal area immune positivity was also analyzed.
Results:
Heterogeneity within ductal carcinoma in situ – single duct analyses within same patients
To evaluate expression heterogeneity of marker expression in ductal carcinoma in situ, we 
analyzed 416 individual ducts involving ductal carcinoma in situ on 13 patient tissue 
sections (average 29 ducts per patient; range: 20–40; Figure 1 and Supplementary Table S1) 
containing a total of 379,408 epithelial cells from 13 cases (average 29,185 cells per patient) 
(Supplementary Table S2). Similarly, 543,355 stromal cells (average 41,796 cells per 
patient) were studied for expression of the three immune markers CD4, CD8, and CD20. 
Using this cellular data, cluster analysis for epithelial markers was performed within ducts, 
between ducts, and between patients. Additional correlation analysis was performed to 
investigate relationships between these epithelial clusters and immune cell infiltration.
Analysis of the markers in the epithelial compartment showed heterogeneity of expression 
within single individual ducts from the same patient (Fig 2A & B; Supplementary Figure 
S1). Expression pattern for markers such as HER4 and HER2 was relatively stable across 
multiple cells/ducts. On the other hand, pmTOR, CD44v6, and CD10 were infrequently 
expressed (5%, 2% and 2% respectively) and varied significantly among cells from the same 
duct (Supplementary Figure S2). To better understand marker co-expression and quantify 
heterogeneity, a clustering algorithm (K-means) was applied to the epithelial cell biomarker 
data. Eight different clusters were identified based on expression of 7 epithelial markers 
(Figure 3A); these cluster IDs were mapped back to the cells as illustrated as in Figure 3B 
(Supplementary Table S3). The proportion of each cluster was quantified and heterogeneity 
was assessed using Shannon Diversity Index. Briefly, Clusters 2 and 8 both showed high 
expression of CD10 and EGFR, but cluster 8 showed low expression of other markers. 
HER2 expression was high in clusters 3 and 7; pmTOR expression was higher in clusters 1–
3 and 5. There was moderate heterogeneity in distribution of 8 clusters within each duct 
(average Shannon Index 0.76; ranged 0 −1.61).
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Heterogeneity within ductal carcinoma in situ – single patient analyses
To further address the issue of the heterogeneity of ductal carcinoma in situ lesions within 
the same patient, the distribution of the clusters was analyzed in different ducts from the 
same patient (Figure 3C and Supplementary Figure S3). Four patients had a dominant 
cellular phenotype (>80%) represented by cluster groups 3 and 7 (high HER2), cluster 6 
(High HER4 and SLC7A5 and low HER2 and pmTOR), or cluster 4 (no dominant markers 
define this group). In 5 patients, the pattern was more heterogeneous with 50–70% of the 
cells belonging to cluster 1 (moderate to high levels for all markers except EGFR and 
CD10). The remaining patients had a strong representation of clusters 4 and 5 (CD44v6 and 
pmTOR) cells. Within each patient, the average Shannon Index across all ducts ranged from 
0.33 to 1.02 (S.D. 0.09 to 0.38). This data documents the presence of high degree of 
heterogeneity at the protein level in patients with ductal carcinoma in situ. Additional 
analyses were performed to estimate the minimal number of ducts required to represent all 8 
clusters. A cluster was deemed to be represented, if more than 5% of the duct cells belong to 
the particular cluster. On average, the number of clusters represented within a single duct 
was 2.5 (range 106), which corresponds to Shannon Index 0.76. As the distribution of 
clusters within ducts is uneven, the analysis of 8 ducts would be sufficient to represent all 8 
clusters i.e. within and between duct heterogeneity.
Correlation of Stromal/Immune Analysis with epithelial expression pattern-
To analyze the impact of heterogeneity on immune infiltration, immune cells were quantified 
in both the stromal and epithelial compartments (representative data in Figure 4A & 4B). 
The stromal tumor infiltrating lymphocytes were classified as (CD20+) B-cells or (CD4+ or 
CD8+) T- cells. The distribution of stromal tumor infiltrating lymphocytes in ductal 
carcinoma in situ cases (Supplementary Table S4) was either a mixed B-cell (CD20+) or T-
cell response (n=10), or one dominated by CD4 T-cells (n=1). The relationship between 
histology and immune markers was assessed in each field of view for all patients (Figure 
5A-C). Although the sample size is small, larger lesion size was positively correlated with 
proportion of cluster 7 (high HER2) cells and CD20 infiltration (P= 0.002 and 0.0027 from 
t-test, respectively). Higher nuclear grade was associated with proportion of epithelial cluster 
5 (high CD44v6 and pmTOR) cells (P value 0.008) and CD20 positivity (P = 0.019; F test). 
The cases were further analyzed as per four subtypes defined by expression of ER, PR and 
HER2 (ER+/PR-/HER2-, ER+/PR+/HER2-, ER+ HER2+, and HER2+) accounting for 3, 7, 
1 and 2 cases, respectively. Proportion of cluster 3 cells was lower in all ER+PR+ cases (P= 
0.05 from F-test). The ER+/HER2- cases had lower representation of cluster 7 cells (P= 0.08 
from F=test). The HER2+ patients had higher B cells irrespective of ER status (F-test; P = 
0.003).
A composite image representing the relationship of the epithelial clusters with immune 
markers is illustrated in Figure 6. This clearly highlights the degree of heterogeneity in 
protein expression in ductal carcinoma in situ. Cluster 2 (high EGFR and CD10 expression) 
was associated with a high T-cell to B-cell ratio (Spearman correlation coefficient = 0.83, P 
= 0.0004), while Cluster 7 (high HER2 expression) was associated with a B-cell response 
(Spearman correlation coefficient = 0.68, P = 0.009). The relative scarcity of intra-epithelial 
tumor infiltrating lymphocytes made correlations difficult.
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Discussion:
Tumors being monoclonal in origin were believed to lack significant cellular diversity. This 
was particularly true for ductal carcinoma in situ, which is thought to arise in/ from terminal 
duct units and then spread outwards to involve the ductal system in a segmental manner. The 
currently used CAP classification system is based on the finding of uniformity of nuclear 
(grade) morphology in ductal carcinoma in situ lesions (32). These factors feed in to the 
notion that ductal carcinoma in situ is a homogeneous lesion. Recent studies have 
documented intra-tumor heterogeneity in several cancers as an important determinant for 
tumor recurrence and resistance to therapy (33). The extent of intra- and inter-ductal 
heterogeneity in ductal carcinoma in situ has not been yet well documented.
The traditional methods of assessing heterogeneity involve studying different regions from 
the same lesion, extracting DNA and studying the mutational profile. This approach is 
excellent for larger lesions and fresh tumors but has limited utility in ductal carcinoma in 
situ, where the lesions are small, and admixed with normal tissues. Furthermore, these 
methods only permit regional assessment of heterogeneity and do not permit single cell 
analysis of lesion diagnosed only after histological examination. Multiplexed 
immunofluorescent staining and single cell analysis of cancer tissue provides a potentially 
powerful approach for measuring tumor cell expression and heterogeneity in intact formalin 
fixed paraffin embedded tissue, avoiding the “grind and find” approach required for genomic 
analyses and potential loss of spatial information(10). Previous work using this multiplexed 
immunofluorescence measured 27 proteins at single cell level in 26 patients with untreated 
stage II/III breast cancer and found 8 clusters of proteins that were co-expressed within the 
tumor region. The ER-negative cluster phenotype was significantly correlated with uptake of 
radiotracer 18F-fluorodeoxyglucose (34). Quantitative intra-tumor spatial heterogeneity 
algorithms have been demonstrated in multiplexed invasive breast cancer (35) and 9 multi-
marker analysis of Reed Sternberg cells has been used for diagnosis of Hodgkin Lymphoma 
(36). Other reports have showed how multiplexing could decipher the complexity of the 
tumor-immune relationships and patient outcomes. Multispectral imaging of CD3, CD8, 
FoxP3, CD163, PD-L1 was used to analyze the tumor microenvironment in melanoma 
patients and predicted ability to generate tumor-infiltrating lymphocytes for T-cell therapy 
(37).
We have therefore applied a multiplex immunofluorescence based approach to study the 
heterogeneity of ductal carcinoma in situ of protein expression pattern in formalin fixed 
paraffin embedded tissues. This analysis is performed on a single 5-micron section and 
represents a paradigm shift in that it permits multiplex in situ protein analysis at the single 
cell level. Furthermore, co-expression analysis, application of clustering algorithms, and 
annotation of the expression data to single cells are possible, while retaining the tissue 
structural context.
Co-expression and correlation analysis of 7 different proteins of epithelial and 3 immune 
origin showed marked differences in expression of proteins in the cells. A single duct was 
found to contain cells located adjacent to one another expressing different proteins. The 
application of K-means clustering identified distinct co-expression profiles within individual 
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cells of the ductal carcinoma in situ lesions. The use of these algorithms, although typical for 
gene expression studies, has not been commonly applied for tissue based protein analysis. 
This analysis identified moderate to marked degree of heterogeneity of protein expression by 
cells within a single duct (average Shannon Index 0.76; range 0 to 1.61). This highlights the 
degree of heterogeneity that is not appreciated by mutational analyses. More importantly, it 
raises the possibility of co-operative action, as a colony, in which single cells could have 
different roles in propagating the growth and progression of the disease.
Further analysis of multiple ducts from the same patient showed moderate degree of 
heterogeneity with individual ducts being composed of one or 2 (co-) dominant clusters/ 
clones or showing a scattered mix of phenotypes. Similar moderate degree of heterogeneity 
was seen in ducts from different patients. Higher expression of cluster 5 cells was associated 
in nuclear grade 2 (P= 0.008; F-test), particularly in ER+ patients. There was also a trend for 
lower cluster 3 and 7 expression in ER+ patients. Grade and ER/PR expression have 
prognostic value in determining the likelihood of recurrence and/or progression to invasive 
cancer. One could postulate that the observed tumor heterogeneity could have a bearing on 
the propensity to recur or progress.
In the current study, specific protein expression profiles were associated with TIL responses. 
In invasive breast cancer, immune cells have been documented to contribute to prognosis 
even in cases treated with chemotherapy (27, 28, 38–40). The amount of tumor infiltrating 
lymphocytes has been correlated with mutational burden in gastrointestinal cancers (41). In 
breast cancer, specific mutational signatures have been associated with tumor infiltrating 
lymphocytes (42). Tantalizingly, an association of epithelial clustering pattern with the 
presence and type of immune infiltrates was observed. This analysis provides the first 
evidence of that simultaneous analysis of both the epithelial and immune/stromal 
components might be necessary to understand the complex milieu in ductal carcinoma in 
situ lesions.
The current study is based on the analysis of a larger number of cells and ducts albeit from a 
limited number of patients with no outcome data (work is ongoing to expand sample size 
with outcomes and will include spatial cell analysis for deeper analysis of cell-to-cell 
interactions and relationships). In spite of these limitations, the study raises several issues 
that are fundamental to understanding of the biology of cancer, particularly breast cancer. 
The study, for the first time, documents the significant heterogeneity in protein expression in 
pre-invasive breast cancer. The documentation of moderate tumor heterogeneity within cells 
of a single duct has profound implications. It seems to suggest that even at the pre-invasive 
stage, cancer is a heterogeneous disease, and perhaps different clones fighting for 
dominance. This is consistent with the stochastic model of cancer evolution (43, 44). On the 
other hand, the finding of single dominant clone in some cases would support the “Big 
Bang” model (45). Does this indicate one should not focus on analyzing mass lesions for 
mutational and protein expression and focus on single cells? Is this the future of single cell 
sequencing? If so, how many cells need to be sequenced is an important question. From the 
patient perspective, “Is heterogeneity or lack of it good?” Homogeneous lesions could 
indicate the establishment of clonal dominance as a sign of aggressiveness. On the other 
hand, as cases with marked heterogeneity would have different clones, one or more of them 
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could survive/ give rise to invasive disease. Understanding the biological impact is 
complicated by the fact that it is rare to see direct progression of ductal carcinoma in situ to 
invasive carcinoma and the low recurrence rates in treated patients. The only way forward is 
to analyze a large series of well annotated cases with established follow-up or a case-control 
design study. The current study provides the scientific basis for the design and performance 
of analysis of well-annotated ductal carcinoma in situ patient cohorts using multiplexed 
immunofluorescence technique and clustering algorithm described herein. These will lead to 
identification of novel clustering patterns that are related with outcomes
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Figure 1: Data collection and analysis workflow.
1A. Tissue sections are scanned for auto-fluorescence and DAPI, and an H&E like image is 
generated allowing for specific regions to be analyzed by multiplex IF.
1B. Enlarged region from H&E scan and a companion composite image of multiplex 
staining for epithelial/ tumor cells (anti-pan cytokeratins AE1 and pck26), CD3 T-Cells, and 
CD20 B-cells are shown.
1C. Output images from single cell analysis workflow showing (left) separation of tumor 
(red) and stroma (green), (middle) single cell segmentation (blue-nuclei, red-epithelial 
membranes, green- epithelial cytoplasm), and (right) mapping of cell expression patterns 
based on K-means clustering back on original images.
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Figure 2: Evaluation of heterogeneity in antibody staining for individual markers.
2A. Representative composite images of staining from a typical ductal carcinoma in situ 
lesion (left), and a region of normal ducts from the same patient sample.
2B: Boxplot of HER4, HER2 and pmTOR intensity for all the cells of one example patient. 
X-axis is the ducts of the lesion. Y-axis is the log2(protein intensity). Within each duct, each 
point is a cell, the black dot is the median cell intensity and the boxplot around the black dot 
is the 25th and 75th quantiles. This figure shows the cell to cell and duct to duct variabilities 
for HER2, HER4 and pmTOR.
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Figure 3: Determining complex patterns of protein expression in ductal carcinoma in situ.
3A. K-means clustering was applied to single cell data to determine patterns of expression 
for 7 markers. Each cluster group represents a pattern of unique cellular expression. Scale 
set with blue representing low/negative expression and red is highest expression.
3B. Cluster IDs mapped back onto images to confirm accuracy of segmentation 
demonstrates variable levels of heterogeneity. Shown are 3 representative cases with high, 
intermediate and low heterogeneity. Colors of cells correspond to color code given to cluster 
groups in figure 3A.
3C. Boxplot of cellular heterogeneity of patients. X-axis is the 8 cell level clusters. Y-axis is 
the percentage of cells within each cluster. Each point is a duct. Most of the ducts for case 5 
has more than 80% cells in cluster 4. Case 10 has majorly cluster 1 and 5. However, case 13 
has 3 main clusters and the percent of cells within each duct can vary from 0–100% for 
cluster 4, 0–90% for cluster 5 and 0–60% for cluster 6.
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Figure 4: Immune quantification in ductal carcinoma in situ samples.
4A. Representative images from 3 cases of ductal carcinoma in situ with differing levels of 
local immune response. Tumor cells (turquoise), CD20 (red), CD4 (green) and CD8 (blue).
4B. Boxplot of immune marker enrichment of patients. X-axis is the 4 main immune types: 
CD4, CD8, CD20 and total T cells (CD4+CD8). Y-axis is the proportion of positive immune 
cells. Each point is a duct. Most of the ducts for case 11 have very few immune cells. Case 6 
has moderate level of immune cells. However, case 1 has relatively higher immune 
proportions for both T cells and B cells.
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Figure 5: Mapping of epithelial and immune components in ductal carcinoma in situ.
5A. Representative pseudo-H&E images showing 4 cases of ductal carcinoma in situ with 
local immune responses.
5B. Composite immunofluorescence images for fields shown in A. Markers include HER4, 
SLC7A5, HER2, pmTOR, CD44v6, CD10 and EGFR.
5C. Cluster IDs mapped back to images allow clear visualization of cells with different 
patterns of expression. Colors correspond to cluster IDs in Figure 3, and pie charts shown in 
inset are for the specific field of view - the inner pie shows relative abundance of the 8 
epithelial groups, and the outer ring show proportions of different immune populations.
5D. Verification of immune patterns after semi-automated quantification. CD20 positive 
cells in red, CD4 in green, and CD8 in blue.
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Figure 6: Summary of epithelial and associated immune patterns in ductal carcinoma in situ.
Pie charts for cluster distribution and immune profile for each patient. The inner pie is 
composed of the 8 epithelial cell clusters. The outer ring is composed of the immune cell 
types as a proportion of the stromal space.
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